RNAi screen analysis of viral host genes
Reference | Disease | Gene | SNP ID | SNP | p-value | Virus |
---|---|---|---|---|---|---|
Reference | Disease | Gene | SNP ID | SNP | p-value | Virus |
22990015 | Stroke (pediatric) | ADAMTS12 | 81792 | rs1364044 | 3.00E-06 | VACV |
20400778 | Mortality among heart failure patients | ADAMTS12 | 81792 | rs6868223 | 2.00E-06 | VACV |
23459443 | QT interval (interaction) | ADAMTSL1 | 92949 | rs1978746 | 8.00E-06 | VACV |
20072603 | Osteoporosis | ALDH7A1 | 501 | rs13182402 | 2.00E-09 | VACV |
21833088 | Multiple sclerosis | ALPK2 | 115701 | rs12456021 | 4.00E-06 | VACV |
22139419 | Mean platelet volume | ANKMY1 | 51281 | rs4305276 | 2.00E-11 | VACV |
23643386 | Weight loss (gastric bypass surgery) | AQP11 | 282679 | rs7129556 | 4.00E-06 | VACV |
21533175 | Dehydroepiandrosterone sulphate levels | ARPC1A | 10552 | rs740160 | 2.00E-16 | VACV |
23400010 | Thiazide-induced adverse metabolic effects in hypertensive patients | ARRB1 | 408 | rs17133858 | 6.00E-06 | VACV |
23728934 | Attention deficit hyperactivity disorder | ARSB | 411 | rs6453417 | 5.00E-06 | VACV |
19668339 | Hippocampal atrophy | ARSB | 411 | rs337847 | 7.00E-06 | VACV |
19084217 | Iron status biomarkers | ARSB | 411 | rs2052550 | 8.00E-06 | VACV |
23144326 | Chronic obstructive pulmonary disease-related biomarkers | ASRGL1 | 80150 | rs2463822 | 1.00E-10 | VACV |
24097068 | HDL cholesterol | ATG7 | 10533 | rs2606736 | 5.00E-08 | VACV |
20038947 | Major depressive disorder (broad) | ATP6V1B2 | 526 | rs1106634 | 7.00E-07 | VACV |
23903356 | Glycemic traits (pregnancy) | BACE2 | 25825 | rs6517656 | 6.00E-16 | VACV |
23251661 | Obesity-related traits | BDP1 | 55814 | rs35131626 | 9.00E-06 | VACV |
23704328 | Primary tooth development (time to first tooth eruption) | BMP4 | 652 | rs17563 | 9.00E-17 | VACV |
23568457 | Bulimia nervosa | CATSPER3 | 347732 | rs299362 | 3.00E-06 | VACV |
21123754 | Alzheimer's disease biomarkers | CCDC134 | 79879 | rs7364180 | 1.00E-06 | VACV |
18794853 | Rheumatoid arthritis | CCL21 | 6366 | rs2812378 | 3.00E-08 | VACV |
21102463 | Crohn's disease | CD244 | 51744 | rs4656940 | 6.00E-07 | VACV |
23555300 | Response to anti-TNF treatment in rheumatoid arthritis | CD84 | 8832 | rs6427528 | 2.00E-06 | VACV |
23128233 | Inflammatory bowel disease | CDC37 | 11140 | rs11879191 | 2.00E-18 | VACV |
23251661 | Obesity-related traits | CEP72 | 55722 | rs7726839 | 1.00E-06 | VACV |
18403759 | YKL-40 levels | CHI3L1 | 1116 | rs4950928 | 1.00E-13 | VACV |
21782286 | Aging (time to event) | COL6A3 | 1293 | rs10202497 | 8.00E-06 | VACV |
23263863 | Platelet counts | COPZ1 | 22818 | rs4326844 | 5.00E-08 | VACV |
23251661 | Obesity-related traits | CPEB4 | 80315 | rs1106693 | 2.00E-06 | VACV |
23128233 | Crohn's disease | CPEB4 | 80315 | rs17695092 | 5.00E-09 | VACV |
20935629 | Waist-hip ratio | CPEB4 | 80315 | rs6861681 | 2.00E-09 | VACV |
20395239 | Optic disc size (cup) | DENND2A | 27147 | rs10237118 | 4.00E-06 | VACV |
23251661 | Obesity-related traits | DPP10 | 57628 | rs6732028 | 3.00E-06 | VACV |
19668339 | Hippocampal atrophy | EFNA5 | 1946 | rs10074258 | 2.00E-07 | VACV |
21531791 | Glioma | EGFR | 1956 | rs11979158 | 7.00E-08 | VACV |
23760081 | Chronic hepatitis B infection | EHMT2 | 10919 | rs652888 | 7.00E-13 | VACV |
21732829 | Dupuytren's disease | EIF3E | 3646 | rs611744 | 8.00E-15 | VACV |
23266558 | Crohn's disease | ELF1 | 1997 | rs7329174 | 8.00E-09 | VACV |
23251661 | Obesity-related traits | ERBB3 | 2065 | rs34379766 | 5.00E-07 | VACV |
21829393 | Type 1 diabetes autoantibodies | ERBB3 | 2065 | rs2292239 | 3.00E-27 | VACV |
20205591 | HIV-1 control | EVI5L | 115704 | rs558718 | 4.00E-06 | VACV |
23144326 | Chronic obstructive pulmonary disease-related biomarkers | EYA1 | 2138 | rs7006821 | 5.00E-06 | VACV |
17903308 | Sleepiness | EYA1 | 2138 | rs2218488 | 3.00E-06 | VACV |
23650146 | Venous thromboembolism | F11 | 2160 | rs4253399 | 3.00E-14 | VACV |
22703881 | Activated partial thromboplastin time | F11 | 2160 | rs1593 | 2.00E-18 | VACV |
21980494 | Venous thromboembolism | F11 | 2160 | rs3756008 | 6.00E-11 | VACV |
22808956 | Antineutrophil cytoplasmic antibody-associated vasculitis | F8 | 2157 | rs17281398 | 4.00E-07 | VACV |
23770605 | Chronic lymphocytic leukemia | FAS | 355 | rs4406737 | 1.00E-14 | VACV |
20694011 | Immunoglobulin A | FAS | 355 | rs2234978 | 6.00E-06 | VACV |
21909115 | Diastolic blood pressure | FES | 2242 | rs2521501 | 2.00E-15 | VACV |
23534349 | QT interval | FGFBP2 | 83888 | rs4698433 | 6.00E-06 | VACV |
18957941 | Personality dimensions | FUNDC1 | 139341 | rs6610953 | 6.00E-06 | VACV |
22139419 | Platelet counts | GP1BA | 2811 | rs6065 | 3.00E-11 | VACV |
23128233 | Inflammatory bowel disease | GPR35 | 2859 | rs3749171 | 3.00E-21 | VACV |
22821403 | Sclerosing cholangitis and ulcerative colitis (combined) | GPR35 | 2859 | rs4676410 | 2.00E-09 | VACV |
22566498 | Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) | GPR83 | 10888 | rs3758785 | 2.00E-06 | VACV |
19801982 | Bone mineral density (hip) | HDAC5 | 10014 | rs228769 | 2.00E-08 | VACV |
23222517 | Red blood cell traits | HK1 | 3098 | rs10159477 | 4.00E-20 | VACV |
20858683 | Glycated hemoglobin levels | HK1 | 3098 | rs16926246 | 3.00E-54 | VACV |
19096518 | Glycated hemoglobin levels | HK1 | 3098 | rs7072268 | 2.00E-25 | VACV |
22939635 | C-reactive protein | HNF1A | 6927 | rs2259816 | 3.00E-10 | VACV |
21203500 | N-glycan levels | HNF1A | 6927 | rs735396 | 4.00E-08 | VACV |
24097068 | Cholesterol, total | HNF1A | 6927 | rs1169288 | 4.00E-17 | VACV |
23844046 | C-reactive protein | HNF1A | 6927 | rs1183910 | 4.00E-12 | VACV |
23263486 | Urate levels | HNF1A | 6927 | rs2244608 | 8.00E-08 | VACV |
22939635 | C-reactive protein | HNF1A | 6927 | rs7979473 | 1.00E-10 | VACV |
22788528 | C-reactive protein and white blood cell count | HNF1A | 6927 | rs2393791 | 3.00E-09 | VACV |
22001757 | Liver enzyme levels (gamma-glutamyl transferase) | HNF1A | 6927 | rs7310409 | 7.00E-45 | VACV |
18439552 | C-reactive protein | HNF1A | 6927 | rs1169310 | 2.00E-08 | VACV |
23284291 | Pulmonary function (interaction) | HTR4 | 3360 | rs11168048 | 5.00E-17 | VACV |
22837378 | Airflow obstruction | HTR4 | 3360 | rs7733088 | 4.00E-09 | VACV |
20010834 | Pulmonary function | HTR4 | 3360 | rs3995090 | 4.00E-09 | VACV |
20838585 | Cardiovascular disease risk factors | IL1RAPL1 | 11141 | rs7890572 | 1.00E-07 | VACV |
19122664 | Ulcerative colitis | IL26 | 55801 | rs2870946 | 5.00E-07 | VACV |
23092984 | Bipolar disorder (mood-incongruent) | INPP4A | 3631 | rs12617721 | 7.00E-06 | VACV |
21658281 | Sudden cardiac arrest | KCTD1 | 284252 | rs16942421 | 8.00E-10 | VACV |
21160077 | Prostate-specific antigen levels | KLK3 | 354 | rs17632542 | 3.00E-46 | VACV |
23251661 | Obesity-related traits | KMO | 8564 | rs1053221 | 1.00E-06 | VACV |
22760553 | Response to citalopram treatment | LAMA1 | 284217 | rs3810046 | 5.00E-07 | VACV |
22693455 | Type 2 diabetes | LAMA1 | 284217 | rs8090011 | 8.00E-09 | VACV |
21408207 | Systemic lupus erythematosus | LAMC2 | 3918 | rs525410 | 6.00E-07 | VACV |
21347282 | Coronary heart disease | LAMC2 | 3918 | rs1028771 | 4.00E-06 | VACV |
23213074 | Non-alcoholic fatty liver disease histology (other) | LCP1 | 3936 | rs7324845 | 3.00E-06 | VACV |
22745009 | Hippocampal atrophy | LHFP | 10186 | rs9315702 | 2.00E-08 | VACV |
23666239 | Testicular germ cell tumor | LIPG | 9388 | rs9951026 | 5.00E-06 | VACV |
23568457 | Bulimia nervosa | MAGI3 | 260425 | rs61742849 | 6.00E-06 | VACV |
19668339 | Hippocampal atrophy | MAL2 | 114569 | rs1364705 | 9.00E-06 | VACV |
21107309 | Reasoning | MAP3K9 | 4293 | rs17108533 | 1.00E-06 | VACV |
22949513 | Epilepsy (generalized) | MAST4 | 375449 | rs39861 | 3.00E-07 | VACV |
20009918 | Carotid atherosclerosis in HIV infection | MAST4 | 375449 | rs1697137 | 2.00E-06 | VACV |
23535732 | Prostate cancer | MDM4 | 4194 | rs4245739 | 2.00E-11 | VACV |
23544013 | Breast Cancer in BRCA1 mutation carriers | MDM4 | 4194 | rs2290854 | 1.00E-07 | VACV |
22589738 | Visceral adipose tissue adjusted for BMI | MICA | 100507436 | rs12175489 | 2.00E-06 | VACV |
21653640 | Rheumatoid arthritis | MICA | 100507436 | rs1063635 | 1.00E-17 | VACV |
21499248 | Hepatocellular carcinoma | MICA | 100507436 | rs2596542 | 4.00E-13 | VACV |
20881960 | Height | MICA | 100507436 | rs2256183 | 8.00E-29 | VACV |
22832961 | Alzheimer's disease | MMP12 | 4321 | rs12808148 | 1.00E-06 | VACV |
19430483 | Systolic blood pressure | MTHFR | 4524 | rs17367504 | 2.00E-13 | VACV |
23824729 | Homocysteine levels | MTHFR | 4524 | rs1801133 | 4.00E-104 | VACV |
19597492 | Atrial fibrillation | MTHFR | 4524 | rs17375901 | 6.00E-07 | VACV |
22137330 | Creutzfeldt-Jakob disease (variant) | MTMR7 | 9108 | rs4921542 | 2.00E-08 | VACV |
24097068 | Cholesterol, total | MYLIP | 29116 | rs3757354 | 2.00E-15 | VACV |
23423138 | Mathematical ability in children with dyslexia | MYO18B | 84700 | rs133885 | 8.00E-10 | VACV |
21294900 | Uric acid levels | MYO18B | 84700 | rs8139900 | 4.00E-06 | VACV |
20713499 | Schizophrenia, bipolar disorder and depression (combined) | MYO18B | 84700 | rs1001021 | 2.00E-06 | VACV |
23533358 | Addiction | NCK2 | 8440 | rs2377339 | 1.00E-11 | VACV |
24026423 | Mean platelet volume | NFE2 | 4778 | rs10506328 | 2.00E-09 | VACV |
23028356 | Rheumatoid arthritis | NFKBIE | 4794 | rs2233434 | 1.00E-15 | VACV |
23007406 | Acute lymphoblastic leukemia (childhood) | NPFFR1 | 64106 | rs41322152 | 8.00E-06 | VACV |
23319000 | Metabolite levels (HVA/MHPG ratio) | NRXN1 | 9378 | rs6750634 | 4.00E-06 | VACV |
22832960 | Temperament | NRXN1 | 9378 | rs6754640 | 1.00E-06 | VACV |
20834067 | Longevity | NRXN1 | 9378 | rs1356888 | 1.00E-06 | VACV |
20691247 | Personality dimensions | NRXN1 | 9378 | rs10176705 | 9.00E-06 | VACV |
23251661 | Obesity-related traits | NUP153 | 9972 | rs2274136 | 3.00E-06 | VACV |
18391951 | Height | NUP153 | 9972 | rs12199222 | 7.00E-07 | VACV |
23934736 | Metabolite levels (Dihydroxy docosatrienoic acid) | NUP98 | 4928 | rs685782 | 7.00E-06 | VACV |
22699663 | Periodontal microbiota | OTOF | 9381 | rs1011108 | 2.00E-06 | VACV |
21658281 | Sudden cardiac arrest | PARP4 | 143 | rs9581094 | 7.00E-07 | VACV |
23563607 | Height | PCSK5 | 5125 | rs11144688 | 4.00E-16 | VACV |
23319000 | Metabolite levels (5-HIAA) | PCSK5 | 5125 | rs7047865 | 5.00E-06 | VACV |
23149075 | Response to fenofibrate (adiponectin levels) | PCSK5 | 5125 | rs10746997 | 1.00E-06 | VACV |
23408906 | Thyroid hormone levels | PDE10A | 10846 | rs753760 | 1.00E-24 | VACV |
20585324 | Conduct disorder (symptom count) | PDE10A | 10846 | rs7762160 | 1.00E-06 | VACV |
23222517 | Red blood cell traits | PIEZO1 | 9780 | rs10445033 | 2.00E-22 | VACV |
21490949 | Type 2 diabetes | PLS1 | 5357 | rs3773506 | 9.00E-06 | VACV |
23535033 | Alzheimer's disease (cognitive decline) | PPAPDC1A | 196051 | rs118048115 | 6.00E-07 | VACV |
20663923 | Autism | PPP2R5C | 5527 | rs7142002 | 3.00E-06 | VACV |
20700443 | Magnesium levels | PRMT7 | 54496 | rs7197653 | 2.00E-06 | VACV |
23563607 | Height | PSMC3 | 5702 | rs10838708 | 2.00E-09 | VACV |
23022100 | Serum albumin level | PSMC3 | 5702 | rs2293579 | 8.00E-08 | VACV |
19820697 | Hematological parameters | PTPN11 | 5781 | rs11066301 | 8.00E-12 | VACV |
22959728 | Amyotrophic lateral sclerosis (age of onset) | PTPRF | 5792 | rs2819332 | 5.00E-06 | VACV |
21546767 | Dialysis-related mortality | PTPRM | 5797 | rs8098064 | 4.00E-06 | VACV |
21546767 | Dialysis-related mortality | PTPRM | 5797 | rs7243299 | 8.00E-06 | VACV |
24026423 | Platelet counts | RCL1 | 10171 | rs423955 | 1.00E-09 | VACV |
23263863 | Mean corpuscular hemoglobin | RCL1 | 10171 | rs10815094 | 5.00E-06 | VACV |
23263863 | Mean corpuscular volume | RCL1 | 10171 | rs2236496 | 2.00E-07 | VACV |
23263863 | Platelet counts | RCL1 | 10171 | rs457287 | 1.00E-06 | VACV |
22139419 | Platelet counts | RCL1 | 10171 | rs13300663 | 1.00E-29 | VACV |
19862010 | Mean corpuscular hemoglobin | RCL1 | 10171 | rs10758658 | 2.00E-14 | VACV |
22843503 | Resistin levels | RETN | 56729 | rs3745367 | 3.00E-06 | VACV |
22139419 | Mean platelet volume | RNF145 | 153830 | rs10076782 | 4.00E-08 | VACV |
20686608 | Pancreatic cancer | RNF43 | 54894 | rs2257205 | 8.00E-06 | VACV |
22589738 | Visceral adipose tissue/subcutaneous adipose tissue ratio | RPS14 | 6208 | rs13177918 | 8.00E-06 | VACV |
22911880 | Eating disorders | RUFY1 | 80230 | rs6894268 | 3.00E-06 | VACV |
20585324 | Conduct disorder (symptom count) | SELPLG | 6404 | rs8179116 | 3.00E-06 | VACV |
23144326 | Chronic obstructive pulmonary disease-related biomarkers | SFTPD | 6441 | rs7078012 | 5.00E-09 | VACV |
22610502 | Immune reponse to smallpox (secreted IL-1beta) | SLC15A1 | 6564 | rs9582259 | 3.00E-08 | VACV |
20860503 | Asthma | SLC22A5 | 6584 | rs2073643 | 2.00E-07 | VACV |
20881960 | Height | SLIT3 | 6586 | rs4282339 | 7.00E-16 | VACV |
21347282 | Coronary heart disease | SMARCA4 | 6597 | rs11669133 | 1.00E-08 | VACV |
21378990 | Coronary heart disease | SMARCA4 | 6597 | rs1122608 | 1.00E-09 | VACV |
23251661 | Obesity-related traits | SP110 | 3431 | rs13010639 | 6.00E-06 | VACV |
23535033 | Alzheimer's disease (cognitive decline) | SP6 | 80320 | rs4794202 | 8.00E-08 | VACV |
22688191 | Bipolar disorder and schizophrenia | SPTLC1 | 10558 | rs7872515 | 6.00E-07 | VACV |
19079261 | Body mass index | STK33 | 65975 | rs10769908 | 1.00E-06 | VACV |
20935630 | Body mass index | STK33 | 65975 | rs4929949 | 3.00E-09 | VACV |
20596022 | Alopecia areata | STX17 | 55014 | rs10760706 | 4.00E-07 | VACV |
21685912 | Progressive supranuclear palsy | STX6 | 10228 | rs1411478 | 4.00E-11 | VACV |
23471985 | Brain connectivity | TACR1 | 6869 | rs3771863 | 3.00E-09 | VACV |
22589738 | Visceral adipose tissue adjusted for BMI | TAF4B | 6875 | rs1791780 | 4.00E-07 | VACV |
23945395 | Type 2 diabetes | TCF7L2 | 6934 | rs7903146 | 2.00E-15 | VACV |
23535729 | Breast cancer | TCF7L2 | 6934 | rs7904519 | 3.00E-08 | VACV |
23544013 | Breast Cancer in BRCA1 mutation carriers | TCF7L2 | 6934 | rs11196174 | 8.00E-07 | VACV |
21347282 | Coronary heart disease | TCF7L2 | 6934 | rs7901695 | 1.00E-06 | VACV |
20081858 | Fasting glucose-related traits | TCF7L2 | 6934 | rs4506565 | 1.00E-08 | VACV |
20081857 | Two-hour glucose challenge | TCF7L2 | 6934 | rs12243326 | 1.00E-07 | VACV |
23612905 | Graves' disease | TG | 7038 | rs2294025 | 8.00E-09 | VACV |
22566634 | Economic and political preferences (time) | THAP2 | 83591 | rs10748180 | 5.00E-06 | VACV |
23229837 | Neuroticism | TMPRSS9 | 360200 | rs4806846 | 8.00E-06 | VACV |
24097066 | Sj?ren's syndrome | TNFAIP3 | 7128 | rs5029939 | 8.00E-09 | VACV |
23273568 | Systemic lupus erythematosus | TNFAIP3 | 7128 | rs2230926 | 1.00E-13 | VACV |
20953190 | Psoriasis | TNFAIP3 | 7128 | rs610604 | 7.00E-07 | VACV |
21654844 | Multiple sclerosis | TRIM2 | 23321 | rs12644284 | 4.00E-06 | VACV |
23535732 | Prostate cancer | TRIM8 | 81603 | rs3850699 | 5.00E-10 | VACV |
23793025 | Migraine | TRPM8 | 79054 | rs6741751 | 9.00E-14 | VACV |
22683712 | Migraine | TRPM8 | 79054 | rs10166942 | 1.00E-12 | VACV |
20031603 | QT interval | TTN | 7273 | rs12476289 | 2.00E-06 | VACV |
21897333 | Fat distribution (HIV) | UBE4A | 9354 | rs502514 | 2.00E-06 | VACV |